Sells hospital medical technologies, plasma-collection systems and software, and blood-component collection products to hospitals, plasma centers and blood centers.
10-K for FY2026, filed May 20, 2026Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our…View ↗
Our Plasma business offers automated plasma collection systems, donor management software and supporting software solutions that enable…View ↗
Our Blood Center business offers a range of products and technologies to help blood centers optimize their blood collections, improve donor…View ↗
Hospitals are called upon to provide the highest standard of patient care while at the same time reducing operating costs. Haemonetics’…View ↗
Hospitals buy medical devices and related products at shipment or delivery; blood and plasma collectors buy equipment and disposables on that basis, while software support spans service periods and some fees depend on collections or use.
10-K for FY2026, filed May 20, 2026
10-K for FY2026, filed May 20, 2026
FY2026 revenue by reportable segment ↗$1.3B
10-K for FY2026, filed May 20, 2026
$1.3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Plasma
|
39% |
Plasma, FY2026
$524.5M Sources
|
|
|
Blood Center
Sold outright
10-K for FY2026, filed May 20, 2026 |
17% |
Blood Center, FY2026
$221.3M Sources
|
Sold outright |
|
Hospital
Sold outright
10-K for FY2026, filed May 20, 2026 |
44% |
Hospital, FY2026
$588.3M Sources
|
Sold outright |
Plasma and blood collection organizations, hospitals and hospital service providers, and purchasing or national health organizations are customers. Sales go through Haemonetics’ direct sales force and independent distributors.
10-K for FY2026, filed May 20, 2026We market and sell our products in approximately 90 countries through a combination of our own direct sales force (including full-time…View ↗
10-K for FY2026, filed May 20, 2026
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and…View ↗
Yes. It kept 7 cents of every revenue dollar as net income in FY2026 and turned 20 cents into free cash flow.
8-K, filed Aug 6, 2026
The Company raised its previous fiscal 2027 GAAP revenue and organic revenue growth guidance as follows:View ↗
Growing. Revenue grew 34% in 4 years, from $993.2M in FY2022 to $1.3B in FY2026, about 8% a year.
Blood Center product line
The older report describes manual whole-blood collection systems and disposable sets; the newer report says the Whole Blood product line was divested and describes automated component systems.
10-K for FY2023, filed May 22, 2023 10-K for FY2026, filed May 20, 2026Blood Center Products — We offer automated blood component systems to blood centers to collect blood products efficiently and cost…View ↗
Hospital product range
The newer report adds sensor-guided technologies and esophageal protection to the Hospital portfolio, alongside vascular closure, hemostasis management, cell salvage and transfusion management.
10-K for FY2023, filed May 22, 2023 10-K for FY2026, filed May 20, 2026Hospitals are called upon to provide the highest standard of patient care while at the same time to reduce operating costs. Haemonetics’…View ↗
Hospitals are called upon to provide the highest standard of patient care while at the same time reducing operating costs. Haemonetics’…View ↗
Sensor-Guided Technologies Products — Our OptoWire® pressure guidewire aims to improve clinical outcomes by accurately and consistently…View ↗
Esophageal ProtectionView ↗
Competes with Fresenius, Terumo Blood and Cell Technologies, Abbott Laboratories, Nigale, Scinomed, Cordis, Teleflex, Boston Scientific, Philips, Werfen, Diagnostica Stago, Sysmex, HemoSonics, LivaNova, Medtronic, WellSky, SSC Soft, Cerner, Clinsys, and MSoft
10-K for FY2026, filed May 20, 2026In the automated plasma collection market, we principally compete with Fresenius’ Fenwal Aurora and Aurora Xi device product lines and…View ↗
Loading...